<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33280015</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1462-0332</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>Suppl5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Rheumatology (Oxford, England)</Title>
          <ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lupus nephritis: clinical presentations and outcomes in the 21st century.</ArticleTitle>
        <Pagination>
          <StartPage>v39</StartPage>
          <EndPage>v51</EndPage>
          <MedlinePgn>v39-v51</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keaa381</ELocationID>
        <Abstract>
          <AbstractText>Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gasparotto</LastName>
            <ForeName>Michela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Unit, Department of Medicine, University of Padua.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gatto</LastName>
            <ForeName>Mariele</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Unit, Department of Medicine, University of Padua.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Binda</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doria</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Unit, Department of Medicine, University of Padua.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moroni</LastName>
            <ForeName>Gabriella</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Rheumatology (Oxford)</MedlineTA>
        <NlmUniqueID>100883501</NlmUniqueID>
        <ISSNLinking>1462-0324</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">B cells</Keyword>
        <Keyword MajorTopicYN="Y">calcineurin inhibitors</Keyword>
        <Keyword MajorTopicYN="Y">classification</Keyword>
        <Keyword MajorTopicYN="Y">lupus nephritis</Keyword>
        <Keyword MajorTopicYN="Y">prognosis</Keyword>
        <Keyword MajorTopicYN="Y">renal biopsy</Keyword>
        <Keyword MajorTopicYN="Y">risk factors</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33280015</ArticleId>
        <ArticleId IdType="pmc">PMC7751166</ArticleId>
        <ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId>
        <ArticleId IdType="pii">6024733</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Davidson A. 
 What is damaging the kidney in lupus nephritis?  Nat Rev Rheumatol  2016;12:143–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4820834</ArticleId>
            <ArticleId IdType="pubmed">26581344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoover PJ, Costenbader KH. 
 Insight into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kideny Int  2016;90:487–92.</Citation>
        </Reference>
        <Reference>
          <Citation>
Hanly JG, O’Keeffe AG, Su L  et al. 
 The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology  2016;55:252–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4939728</ArticleId>
            <ArticleId IdType="pubmed">26342222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Doria A, Iaccarino L, Ghirardello A  et al. 
 Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med  2006;119:700–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16887417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bastian HM, Roseman JM, McGwin GJ  et al. 
 Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus  2002;11:152–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12004788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Depetri F, Ponticelli C. 
 Lupus nephritis: when and how often to biopsy and what does it mean?  J Autoimmun  2016;74:27–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27349351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wada Y, Ito S, Ueno M  et al. 
 Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract  2004;98:c105–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15627787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Balow JE. 
 Clinical presentation and monitoring of lupus nephritis. Lupus  2005;14:25–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15732284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Vercelloni PG, Quaglini S  et al. 
 Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis  2018;77:1318–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29730634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petri M, Orbai A-M, Alarcón GS  et al. 
 Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum  2012;64:2677–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3409311</ArticleId>
            <ArticleId IdType="pubmed">22553077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aringer M, Costenbader K, Daikh D  et al. 
 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis  2019;78:1151–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31383717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH. 
 Glomerular disease: lupus nephritis treatment: are we beyond cyclophosphamide?  Nat Rev Nephrol  2009;5:492–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19701224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mittal B, Rennke H, Singh AK. 
 The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens  2005;14:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15586009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zabaleta-Lanz M, Vargas-Arenas RE, Tápanes F  et al. 
 Silent nephritis in systemic lupus erythematosus. Lupus  2003;12:26–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12587823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hahn BH, McMahon MA, Wilkinson A  et al. 
 American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res  2012;64:797–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3437757</ArticleId>
            <ArticleId IdType="pubmed">22556106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haładyj E, Cervera R. 
 Do we still need renal biopsy in lupus nephritis?  Reumatologia  2016;2:61–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4918045</ArticleId>
            <ArticleId IdType="pubmed">27407281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fanouriakis A, Kostopoulou M, Cheema K. 
 2019 update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis  2020;79:713–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32220834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hebert LA, Parikh S, Prosek J  et al. 
 Differential diagnosis of glomerular disease: a systematic and inclusive approach. Am J Nephrol  2013;38:253–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3842189</ArticleId>
            <ArticleId IdType="pubmed">24052039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bihl GR, Petri M, Fine DM. 
 Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant  2006;21:1749–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16632559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giannico G, Fogo AB. 
 Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?  Clin J Am Soc Nephrol  2013;8:138–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22977215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Christopher-Stine L, Siedner M, Lin J  et al. 
 Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol  2007;34:332–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17183619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bertsias GK, Tektonidou M, Amoura Z  et al. 
 Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis  2012;71:1771–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3465859</ArticleId>
            <ArticleId IdType="pubmed">22851469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fogo AB. 
 Approach to renal biopsy. Am J Kidney Dis  2003;42:826–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14520635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Pasquali S, Quaglini S  et al. 
 Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis  1999;34:530–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10469865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anders H-J. 
 Re-biopsy in lupus nephritis. Ann Transl Med  2018;6:S41–S41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6291576</ArticleId>
            <ArticleId IdType="pubmed">30613616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Rosa M, Azzato F, Toblli JE  et al. 
 A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int  2018;94:788–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30045812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. 
 Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med  2014;1:e000018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4213828</ArticleId>
            <ArticleId IdType="pubmed">25379188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malvar A, Pirruccio P, Alberton V  et al. 
 Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant  2017;32:1338–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5837387</ArticleId>
            <ArticleId IdType="pubmed">26250434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anders H-J, Rovin B. 
 A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int  2016;90:493–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27378475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weening JJ, D'agati VD, Schwartz MM  et al. 
 The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int  2004;65:521–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14717922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bajema IM, Wilhelmus S, Alpers CE  et al. 
 Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions and modified National Institutes of Health activity and chronicity indices. Kidney Int  2018;93:789–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29459092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Al Arfaj AS, Khalil N, Al Saleh S. 
 Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol Int  2009;29:1057–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19381639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mok C, Cheung T, Lo W. 
 Minimal mesangial lupus nephritis: a systematic review. Scand J Rheumatol  2010;39:181–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20166847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chang JH, Kim DK, Kim HW  et al. 
 Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant  2009;24:2406–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19264742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang J, Liang D, Zhang H  et al. 
 Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus  2015;24:1468–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26139236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huong DL, Papo T, Beaufils H  et al. 
 Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine  1999;78:148–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10352647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang H, Ren Y, Chang J  et al. 
 A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol  2018;33:17–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5864167</ArticleId>
            <ArticleId IdType="pubmed">29900975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tam LS, Li EK, Lai FM  et al. 
 Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus  2003;12:665–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14514128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee SG, Cho YM, So MW  et al. 
 ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not. Rheumatol Int  2012;32:2459–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21769491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Collado MV, Dorado E, Rausch S  et al. 
 Long-term Outcome of Lupus Nephritis Class II in argentine patients: an open retrospective analysis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis  2016;22:299–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4998123</ArticleId>
            <ArticleId IdType="pubmed">27152693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Quaglini S, Gravellone L  et al. 
 Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum  2012;41:642–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22285127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Austin HA, Illei GG. 
 Membranous lupus nephritis. Lupus  2005;14:65–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15732291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haring CM, Rietveld A, Van den Brand J, Berden J. 
 Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol  2012;23:149–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3269930</ArticleId>
            <ArticleId IdType="pubmed">22034639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stokes MB, D'Agati VD. 
 Classification of Lupus Nephritis;  Time for a Change? Adv Chronic Kidney Dis  2019;26:323–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31733716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen D, Hu W. 
 Lupus podocytopathy: a distinct entity of lupus nephritis. J Nephrol  2018;31:629–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29270846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bomback AS, Markowitz GS. 
 Lupus podocytopathy: a distinct entity. Clin J Am Soc Nephrol  2016;11:547–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822655</ArticleId>
            <ArticleId IdType="pubmed">26983708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hu W, Chen Y, Wang S  et al. 
 Clinical–morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol  2016;11:585–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822663</ArticleId>
            <ArticleId IdType="pubmed">26983707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rezende G, Viana V, Malheiros D  et al. 
 Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?  Lupus  2014;23:255–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24356611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu F, Haas M, Glassock R, Zhao M-H. 
 Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol  2017;13:483–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28669995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Felson DT, Anderson J. 
 Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med  1984;311:1528–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6390198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Austin HA, Klippel JH, Balow JE  et al. 
 Therapy of lupus nephritis. N Engl J Med  1986;314:614–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3511372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ginzler EM, Dooley MA, Aranow C  et al. 
 Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med  2005;353:2219–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16306519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Appel GB, Contreras G, Dooley MA  et al. 
 Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol  2009;20:1103–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2678035</ArticleId>
            <ArticleId IdType="pubmed">19369404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lenz O, Waheed AA, Baig A  et al. 
 Lupus nephritis: maintenance therapy for lupus nephritis—do we now have a plan?  Clin J Am Soc Nephrol  2013;8:162–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22917704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Houssiau FA, Vasconcelos C, D’Cruz D  et al. 
 The 10-year follow-up data of the Euro Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis  2010;69:61–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19155235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fanouriakis A, Kostopoulou M, Alunno A  et al. 
 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis  2019;78:736–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30926722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou T, Lin S, Yang S, Lin W. 
 Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther  2019;13:857–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6420100</ArticleId>
            <ArticleId IdType="pubmed">30880918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Z, Zhang H, Liu Z  et al. 
 Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med  2015;162:18–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25383558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang H, Liu Z, Zhou M  et al. 
 Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol  2017;28:3671–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698076</ArticleId>
            <ArticleId IdType="pubmed">28760751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen W, Liu Q, Chen W  et al. 
 Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus  2012;21:944–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22438027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Doria A, Ponticelli C. 
 Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant  2008;24:15–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18852191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhong Z, Li H, Zhong H, Zhou T. 
 Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther  2019;13:845–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6417005</ArticleId>
            <ArticleId IdType="pubmed">30880917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alshaiki F, Obaid E, Almuallim A  et al. 
 Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol  2018;5:118–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6072690</ArticleId>
            <ArticleId IdType="pubmed">30185361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Merrill JT, Neuwelt CM, Wallace DJ  et al. 
 Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum  2010;62:222–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4548300</ArticleId>
            <ArticleId IdType="pubmed">20039413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH, Furie R, Latinis K  et al. 
 Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum  2012;64:1215–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22231479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Condon MB, Ashby D, Pepper RJ  et al. 
 Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis  2013;72:1280–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23740227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Raffiotta F, Trezzi B  et al. 
 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology  2014;53:1570–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24505125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sanz I. 
 Extent and patterns of off-label use of rituximab for SLE. Nat Rev Rheumatol  2016;12:700–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5476200</ArticleId>
            <ArticleId IdType="pubmed">27872475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iaccarino L, Bartoloni E, Carli L  et al. 
 Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol  2015;33:499–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26053285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ezeonyeji A, Isenberg D. 
 Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology  2012;51:476–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22096015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Gatto M, Raffiotta F  et al. 
 Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev  2018;17:11–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29108824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lightstone L, Doria A, Wilson H  et al. 
 Can we manage lupus nephritis without chronic corticosteroids administration?  Autoimmun Rev  2018;17:4–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29108828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen X, Jiang H, Ying M  et al. 
 Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep  2016;6:32087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5007516</ArticleId>
            <ArticleId IdType="pubmed">27580845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faul C, Donnelly M, Merscher-Gomez S  et al. 
 The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med  2008;14:931–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4109287</ArticleId>
            <ArticleId IdType="pubmed">18724379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wilhelmus S, Bajema IM, Bertsias GK  et al. 
 Lupus nephritis management guidelines compared. Nephrol Dial Transplant  2016;31:904–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25920920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pons-Estel GJ, Alarcón GS, McGwin G Jr  et al. 
 Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum  2009;61:830–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898742</ArticleId>
            <ArticleId IdType="pubmed">19479701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cunha C, Alexander S, Ashby D  et al. 
 Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?  Nephrol Dial Transplant  2018;33:1604–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7170714</ArticleId>
            <ArticleId IdType="pubmed">29186572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Siso A, Ramos-Casals M, Bove A  et al. 
 Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus  2008;17:281–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Clowse ME, Magder L, Witter F, Petri M. 
 Hydroxychloroquine in lupus pregnancy. Arthritis Rheum  2006;54:3640–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17075810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lightstone L, Hladunewich M. 
 Lupus nephritis and pregnancy: concerns and management. Semin Nephrol  2017.  Jul;37:347–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28711073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sprangers B, Monahan M, Appel GB. 
 Diagnosis and treatment of lupus nephritis flares—an update. Nat Rev Nephrol  2012;8:709–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23147758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Quaglini S, Maccario M  et al. 
 “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int  1996;50:2047–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8943489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gordon C, Jayne D, Pusey C  et al. 
 European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus  2009;18:257–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19213865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davidson JE, Fu Q, Ji B  et al. 
 Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol  2018;45:671–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5932209</ArticleId>
            <ArticleId IdType="pubmed">29496892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen Y, Korbet S, Katz R  et al. 
 Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol  2008;3:46–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2390978</ArticleId>
            <ArticleId IdType="pubmed">18003764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G. 
 Gatto M. 
 Tamborini F  et al. 
 Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis [published online ahead of print, 2020 Jun 5]. Ann Rheum Dis. 2020;annrheumdis-2020-216965. 10.1136/annrheumdis.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis</ArticleId>
            <ArticleId IdType="pubmed">32503858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Houssiau FA, Vasconcelos C, D'Cruz D  et al. 
 Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum  2004;50:3934–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15593207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tamirou F, Lauwerys BR, Dall'Era M  et al. 
 A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med  2015;2:e000123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4654096</ArticleId>
            <ArticleId IdType="pubmed">26629352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fung WA, Su J, Touma Z. 
 Predictors of good long-term renal outcomes in lupus nephritis: results from a single lupus cohort. Biomed Res Int  2017;2017:5312960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5585546</ArticleId>
            <ArticleId IdType="pubmed">28904963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mackay M, Dall'Era M, Fishbein J  et al. 
 Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol  2019;71:411–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30225865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mak A, Cheung M-L, Chiew HJ  et al. 
 Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum  2012;41:830–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22257558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cameron JS. 
 Lupus nephritis. J Am Soc Nephrol  1999;10:413–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10215343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Croca SC, Rodrigues T, Isenberg DA. 
 Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology  2011;50:1424–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21415024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ward MM. 
 Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol  2009;36:63–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679678</ArticleId>
            <ArticleId IdType="pubmed">19004042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tektonidou MG, Dasgupta A, Ward MM. 
 Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol  2016;68:1432–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5071782</ArticleId>
            <ArticleId IdType="pubmed">26815601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reppe Moe SE, Molberg Ø, Strøm EH, Lerang K. 
 Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus  2019;28:818–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31072277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jakes RW, Bae S-C, Louthrenoo W  et al. 
 Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res  2012;64:159–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22052624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Korbet SM, Schwartz MM, Evans J, Lewis EJ. 
 Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol  2007;18:244–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17167111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Contreras G, Pardo V, Cely C  et al. 
 Factors associated with poor outcomes in patients with lupus nephritis. Lupus  2005;14:890–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16335581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Contreras G, Lenz O, Pardo V  et al. 
 Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int  2006;69:1846–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16598205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Almaani S, Meara A, Rovin BH. 
 Update on lupus nephritis. Clin J Am Soc Nephrol  2017;12:825–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5477208</ArticleId>
            <ArticleId IdType="pubmed">27821390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barr RG, Seliger S, Appel GB  et al. 
 Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant  2003;18:2039–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13679478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hsu C-Y, Chiu W-C, Yang T-S  et al. 
 Age- and gender-related long-term renal outcome in patients with lupus nephritis. Lupus  2011;20:1135–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21719527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Carvalho JF, Do Nascimento AP, Testagrossa LA  et al. 
 Male gender results in more severe lupus nephritis. Rheumatol Int  2010;30:1311–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19784840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Donadio JVJ, Hart GM, Bergstralh EJ, Holley KE. 
 Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus  1995;4:109–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7795613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Quaglini S, Gallelli B  et al. 
 The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant  2007;22:2531–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17510096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abbate M, Zoja C, Remuzzi G. 
 How does proteinuria cause progressive renal damage?  J Am Soc Nephrol  2006;17:2974–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17035611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. 
 Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int  1994;45:544–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8164443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
HA A 3rd, Boumpas DT, Vaughan EM, Balow JE. 
 High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant  1995;10:1620–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8559480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leatherwood C, Speyer CB, Feldman CH  et al. 
 Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Semin Arthritis Rheum  2019;49:396–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6888990</ArticleId>
            <ArticleId IdType="pubmed">31277928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hsieh C, Chang A, Brandt D  et al. 
 Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res  2011;63:865–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3106120</ArticleId>
            <ArticleId IdType="pubmed">21309006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mok CC. 
 Prognostic factors in lupus nephritis. Lupus  2005;14:39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15732286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maria NI, Davidson A. 
 Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol  2020;16:255–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32203285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gatto M, Iaccarino L, Ghirardello A, Punzi L, Doria A. 
 Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: a comprehensive review. J Autoimmun  2016;69:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26879422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gatto M, Ghirardello A, Luisetto R  et al. 
 Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. Compr Perspect Syst Lupus Erythematosus  2016;74:208–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27405845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gatto M, Zen M, Iaccarino L, Doria A. 
 New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol  2019;15:30–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30538302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gatto M, Saccon F, Zen M  et al. 
 Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. Compr Perspect Syst Lupus Erythematosus  2016;74:94–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27373904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV). https://clinicaltrials.gov/ct2/show/NCT02141672.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Aurinia Renal Response in Active Lupus with Voclosporin (AURORA). https://www.clinicaltrials.gov/ct2/show/NCT03021499.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (AURORA2). https://www.clinicaltrials.gov/ct2/show/NCT03597464.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Efficacy and safety of Belimumab in patients with active Lupus Nephritis (BLISS_LN). https://clinicaltrials.gov/ct2/show/NCT01639339? term=NCT01639339&amp;rank=1.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Rituximab and Belimumab for Lupus Nephritis (CALIBRATE). http://clinicaltrials.gov/ct2/show/NCT02260934.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. A study to evaluate the efficacy and safety of obinutuzumab in patients with ISN/RPS 2003 Class III or IV lupus nephritis. https://www.clinicaltrials.gov/ct2/show/NCT04221477.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. A study to evaluate the safety and efficacy of obinutuzumab compared with placebo in participants with Lupus Nephritis (LN). https://clinicaltrials.gov/ct2/show/NCT02550652.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis (TULIP-LN1). https://www.clinicaltrials.gov/ct2/show/NCT02547922</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. An investigational study to evaluate the safety and effectiveness of BMS-986165 with background treatment in participants with lupus nephritis. https://www.clinicaltrials.gov/ct2/show/NCT03943147.</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE). https://www.clinicaltrials.gov/ct2/show/NCT04181762.</Citation>
        </Reference>
        <Reference>
          <Citation>
Dooley MA, Pendergraft W III, Ginzler EM  et al. 
 Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract]. Arthritis Rheumatol  2016;68 (suppl 10): Abstract number: 5L.</Citation>
        </Reference>
        <Reference>
          <Citation>
Iaccarino L, Bettio S, Reggia R  et al. 
 Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res  2017;69:115–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27390293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sciascia S, Radin M, Yazdany J  et al. 
 Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev  2017;16:287–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28147262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dall’Era M, Aranow C, Byron M  et al. 
 Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis [abstract]. Arthritis Rheumatol  2018;70:(suppl 10): Abstract number: 1870.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gualtierotti R, Borghi MO, Gerosa M  et al. 
 Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. Clin Exp Rheumatol  2018;36:643–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29533753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murphy G, Isenberg DA. 
 New therapies for systemic lupus erythematosus—past imperfect, future tense. Nat Rev Rheumatol  2019;15:403–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31165780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. A study to evaluate the efficacy and safety of belimumab administered in combination with rituximab to adult subjects with systemic lupus erythematosus (SLE) - BLISS-BELIEVE. https://clinicaltrials.gov/ct2/show/NCT03312907.</Citation>
        </Reference>
        <Reference>
          <Citation>
Schindler T, Rovin B, Furie R  et al. 
 AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN). Ann Rheum Dis  2016;75:1051.2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie RA
 Morand EF
 Bruce IN. 
et al. 
 Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol  2019;1:e208–19.</Citation>
        </Reference>
        <Reference>
          <Citation>
Winthrop KL. 
 The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol  2017;13:234–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28250461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apostolidis SA, Crispín JC, Tsokos GC. 
 IL-17-producing T cells in lupus nephritis. Lupus  2011;20:120–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21303828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crispín JC, Oukka M, Bayliss G  et al. 
 Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol  2008;181:8761–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596652</ArticleId>
            <ArticleId IdType="pubmed">19050297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pisitkun P, Ha H-L, Wang H  et al. 
 Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity  2012;37:1104–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3594848</ArticleId>
            <ArticleId IdType="pubmed">23123062</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
